Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Biopharma Rises 22% Following $394 Million Hong Kong IPO

publication date: Dec 24, 2018

Shanghai Junshi Biosciences rose 22% in its first trading session on the Hong Kong Exchange following its $394 million IPO. Last week, Junshi announced its lead drug candidate, Tuoyi (toripalimab), an anti-PD-1 molecule, was approved by China's NMPA as a second-line treatment for melanoma. It is the first domestic PD-1 approved in China. Junshi has 13 products in development, five of them clinical stage. The IPO was completed at a nearly $2 billion valuation, and the company now has a market capitalization of $2.4 billion. More details....

Stock Symbol: (HK: 1877)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital